Seoul, South Korea-headquartered Boryung Co. Ltd. grabbed headlines in 2022 with its strategic redesign to move beyond drug development, announcing that it would invest $10 million in Axiom Space Inc. for a 0.4% stake in the U.S. commercial space station developer. The investment ramped up over the course of a year, with Boryung pouring a total of $60 million into Axiom Space over two financing rounds for a 2.7% stake. Axiom is set to build the world’s first commercial space station.
Opthea Ltd. plans to raise AU$80 million (US$51.2 million) via a AU$10 million private placement and a AU$70 million entitlement offer to continue its pivotal phase III trials in wet age-related macular degeneration (wet AMD) for lead candidate OPT-302.
Curvebeam AI Ltd. made its debut on the Australian Securities Exchange (ASX:CVB) after raising AU$25 million (US$16.175 million) in an initial public offering that will allow the company to market its flagship Hirise weight-bearing CT scan solution globally.
Fore Biotherapeutics Inc. has closed on a $75 million series D financing so that it can continue developing its lead asset, plixorafenib, an oral small molecule that selectively inhibits BRAF alterations.
Rapport Therapeutics Inc. raised $150 million in a series B round, less than six months after unveiling its $100 million series A investment. It’s further evidence that its distinctive precision neuromedicine approach has gained traction with some deep-pocketed investors and adds further momentum both to its clinical development and its discovery research efforts.
RSS
